Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.41 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12505776 | 0.98 | NOTUM (0.40) | NOTUMARPDE3BPDE3A | |
| SCHEMBL1899441 | 0.98 | NOTUM (0.40) | NOTUMARPDE3BPDE3A | |
| SCHEMBL16719169 | 0.85 | NCF1 (0.45) | — | |
| SCHEMBL605920 | 0.85 | ASIC3 (0.43) | PDE3BPDE3A | |
| SCHEMBL3603722 | 0.85 | AKR1C3 (0.46) | NOTUMPDE3BPDE3AAKR1C3 | |
| SCHEMBL27677143 | 0.82 | KMT2A (0.41) | PDE3BPDE3AAKR1C3 | |
| SCHEMBL18039581 | 0.81 | CHRM4 (0.39) | — | |
| SCHEMBL606783 | 0.78 | NPSR1 (0.39) | — | |
| SCHEMBL282609 | 0.76 | HRH4 (0.39) | NOTUM | |
| SCHEMBL1901740 | 0.76 | ALDH1A1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497273-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20100048582-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-02-25 | — | — | US | disclosed |
| EP-2074110-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2009-07-01 | — | — | EP | disclosed |
| CN-101421264-A | Is suitable for treating serotonin 5HT6Heterocyclic compounds for receptor-modulated responsive disorders | ABBOTT GMBH & CO KG (DE) | 2009-04-29 | — | — | CN | disclosed |
| WO-2007118900-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048582-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | HTR6, HTR1A, HTR2C | NOTUM 3380/4885AR 927/4885PDE3B 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.